Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Express Scripts
US Army
UBS
Chubb
US Department of Justice
Moodys
Queensland Health

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TROPICAMIDE

« Back to Dashboard

Clinical Trials for Tropicamide

Trial ID Title Status Sponsor Phase Summary
NCT00120432 Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation Completed Khon Kaen University Phase 3 The purpose of this study is to compare the efficacy on pupillary dilation between the single dose versus the three doses of 1% tropicamide with 10% phenylephrine for complete ocular examination.
NCT00500344 CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography Unknown status Genentech, Inc. Phase 1 CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
NCT00500344 CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography Unknown status Washington University School of Medicine Phase 1 CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
NCT00501878 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides Completed Khon Kaen University Phase 4 To compare the clinical efficacy and systemic side effects between 2.5% and 10% phenylephrine for mydriasis in diabetic patient with darkly pigmented irides.
NCT00541177 Study of Myopia Prevention in Children With Low Concentration of Atropine Unknown status Min-Sheng General Hospital Phase 4 The purpose of this study is to test the hypothesis that myopia can be prevented by using a low concentration of atropine eyedrops once a week.
NCT00642135 CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment Terminated Ioltech Phase 3 Pupillary dilation to perform a fundus in premature newborns and neonates is often difficult to obtain, because of the non mature iris sphincter. The fundus is essential to detect retinal anomalies (as retinopathy of prematurity or chorioretinal or disk anomalies). The aim of the study is to obtain a satisfactory degree of mydriasis with a minimal dose of two mydriatic treatments, with an optimal duration and a good tolerance of the drugs. The study will evaluate the mydriasis in premature newborns, neonates and infants justifying a mydriasis for a bilateral diagnosis fundus, using ophthalmic insert Mydriasert® versus reference treatment (association of phenylephrine and tropicamide eyedrops). Ophthalmic insert Mydriasert® can control drug dispensation and decrease the number of nurse interventions to obtain mydriasis in patients.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tropicamide

Condition Name

Condition Name for Tropicamide
Intervention Trials
Healthy 1
Refractive Errors 1
Age-Related Macular Degeneration 1
Glaucoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tropicamide
Intervention Trials
Mydriasis 3
Sialorrhea 2
Refractive Errors 1
Premature Birth 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tropicamide

Trials by Country

Trials by Country for Tropicamide
Location Trials
United States 5
France 4
Thailand 3
Argentina 1
Chile 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tropicamide
Location Trials
Massachusetts 2
North Carolina 1
Minnesota 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tropicamide

Clinical Trial Phase

Clinical Trial Phase for Tropicamide
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tropicamide
Clinical Trial Phase Trials
Completed 7
Unknown status 4
Not yet recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tropicamide

Sponsor Name

Sponsor Name for Tropicamide
Sponsor Trials
Khon Kaen University 3
NeuroHealing Pharmaceuticals Inc. 2
Michael J. Fox Foundation for Parkinson's Research 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tropicamide
Sponsor Trials
Other 16
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Teva
Harvard Business School
Fish and Richardson
Dow
Farmers Insurance
Chinese Patent Office
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.